873372-30-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-broMoMethyl-phenyl)-cyclopropanecarboxylic acid Methyl ester is used as a reagent for the preparation of quaternary amines. Quaternary amines are important compounds in the pharmaceutical industry, as they possess antimicrobial, antifungal, and cationic surfactant properties. They are used in the synthesis of various drugs, including antiseptics, disinfectants, and fabric softeners.
Used in Respiratory Disease Treatment:
1-(4-broMoMethyl-phenyl)-cyclopropanecarboxylic acid Methyl ester is also used in the development of epithelial sodium channel (ENaC) inhibitors. ENaC plays a crucial role in the regulation of sodium transport across the epithelial cells in the lungs. Inhibition of ENaC has been shown to reduce mucus viscosity and improve lung function in patients with respiratory diseases such as cystic fibrosis and chronic obstructive pulmonary disease (COPD). By targeting ENaC, 1-(4-broMoMethyl-phenyl)-cyclopropanecarboxylic acid Methyl ester has the potential to provide therapeutic benefits in the treatment of these conditions.

Upstream product

• 959632-00-9 methyl 1-(p-tolyl)cyclopropanecarboxylate 
• 83846-66-6 1-(4-methylphenyl)cyclopropanecarboxylic acid 

Downstream Products

• 1415323-20-4 1-(4-(1-(methoxycarbonyl)cyclopropyl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid 
• 1416069-74-3 methyl 1-(4-((3-benzoylphenoxy)methyl)phenyl)cyclopropanecarboxylate 
• 1416069-77-6 1-(4-((3-(azido(phenyl)methyl)phenoxy)methyl)phenyl)-cyclopropanecarboxylic acid 
• 1416069-76-5 methyl 1-(4-((3-(azido(phenyl)methyl)phenoxy)methyl)-phenyl)cyclopropanecarboxylate 
• 1416069-75-4 methyl 1-(4-((3-(hydroxy(phenyl)methyl)phenoxy)-methyl)phenyl)cyclopropanecarboxylate 
• 1428342-78-2 methyl (S)-1-(4-((2,3-dimethyl-5-((1-(3-(prop-1-en-2-yl)phenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylate 
• 1415323-22-6 methyl (S)-1-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylate 
• 1415323-21-5 methyl (S)-1-(4-((5-((1-(3-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylate 
• 1415321-40-2 (S)-1-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylic acid 

Relevant academic research and scientific papers

PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARy), inhibit cdJk5-mediated phosphorylation of PP ARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

N-BENZYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. Side effects such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, can be avoided in the mammal receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.

FXR AGONISTS

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.